Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML

View Full Paper
Ask AI
Bookmark
Share

Authors

CGCarlo Gambacorti‐Passerini

Discussion

Loading...

Member takes

Overview

Case series shows effective Ponatinib and Asciminib treatment in CML blast crisis, suggesting a safer route to transplant.

Key Points

  • Evaluate effectiveness and safety of Ponatinib and Asciminib in TKI-resistant CML blast crisis patients.
  • Three CML patients treated with Ponatinib and Asciminib at an Italian hematology center.
  • Doses: Ponatinib 45 mg daily; Asciminib 200 mg twice daily until hematologic response.
  • Responses assessed via Complete Hematologic Response, Cytogenetic Response, and BCR:ABL1 transcripts monitoring.
  • All three patients achieved Complete Hematologic Response by Day 28.
  • Cytogenetic Response varied, enabling patients to proceed to allogeneic stem cell transplantation.
  • No severe nonhematologic toxicities reported, with one acute myocardial infarction noted.

Cite This Study

Carlo Gambacorti‐Passerini (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbechttps://doi.org/10.1182/blood-2025-7301
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib a new player in treatment of TKI-resistant/intolerant chronic phase chronic myelogenous leukemia2024 · 2 citations
  2. 2Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025
  3. 3Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  4. 4Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results2024 · 55 citations
  5. 5Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study2025